Medinet CoTSE:2370 41 Net Margin % is -91.07% as of Mar. 2026. GuruFocus rates TSE:2370 with a GF Score™ of 41/100 and a GF Value™ of 円41.74 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 941 Biotechnology companies, Medinet Co ranks worse than 56.43% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Medinet Co's Net Income for the
three
months ended in Mar. 2026 was 円-212.1 Mil. Medinet Co's Revenue for the
three
months ended in Mar. 2026 was 円232.9 Mil. Therefore, Medinet Co's net margin for the quarter that ended in Mar. 2026 was -91.07%.
The historical rank and industry rank for Medinet Co's Net Margin % or its related term are showing as below:
TSE:2370'
s Net Margin % Range Over the Past 10 Years
Min: -326.57 Med: -159.49 Max: -75.1
Current: -147.38
TSE:2370's Net Margin % is ranked worse than 56.43% of 941
companies
in the Biotechnology industry
Industry Median: -88.29
vs TSE:2370: -147.38
Medinet Co (TSE:2370) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Medinet Co Net Margin % Related Terms
Medinet Co Net Margin % Historical Data
* Premium members only.
The historical data trend for Medinet Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2370 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Medinet Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinet Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medinet Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Medinet Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinet Co (TSE:2370) has a Net Margin % of -91.07% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Medinet Co and its competitors. According to the industry distribution chart, Medinet Co ranks #531 out of 941 companies in the Biotechnology industry, placing it in the top 56.4%.
Is Medinet Co's Net Margin % too high?
Medinet Co's current Net Margin % is -91.07%. Based on the distribution chart, Medinet Co ranks #531 out of 941 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Medinet Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medinet Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medinet Co ranks #531 out of 941 companies for Net Margin %. This places Medinet Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Medinet Co and its competitors. Medinet Co's current Net Margin % is -91.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinet Co stock overvalued right now?
Based on GuruFocus' analysis, Medinet Co (TSE:2370) is currently considered Possible Value Trap. The stock's GF Value™ is 円41.74, compared to a current price of 円25.00 — trading 40.1% below its estimated fair value. The current Net Margin % is -91.07%. Medinet Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Medinet Co (TSE:2370), the current Net Margin % is -91.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinet Co (TSE:2370) Overvalued in 2026?
Based on GuruFocus' analysis, Medinet Co stock appears to be undervalued.
The current stock price of 円25.00 is trading 40.1% below its estimated GF Value™ of 円41.74.
GuruFocus considers Medinet Co to be Possible Value Trap.
Key valuation signals for TSE:2370:
Net Margin %: -91.07%
GF Value™: 円41.74 vs. price of 円25.00 (40.1% below fair value)
No single metric tells the full story. See the TSE:2370 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinet Co Ltd is a Japan-based Contract Development and Manufacturing Organization (CDMO). The company is engaged in the research and development of regenerative medical products, investigational products, and specified cell products. MEDINET is a one-stop regenerative medicine and cell therapy solution provider. It provides value chain solutions including personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management solutions to medical institutions, research institutions, and biopharmaceutical companies.
41GF Score
Get the complete analysis for TSE:2370
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2370 has been successfully added to your 
